Clinical Trial Supplies Industry Overview

The global clinical trial supplies market size was estimated at USD 2.58 billion in 2023 and is anticipated to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. Globalization, and rise in the number of biologics  biosimilar drugs in clinical trials are among the major factors expected to drive the market growth. Rapid adoption of a supply chain management system to surmount RD expenditure pressure and increase operational efficiency, as clinical trial supplies account for a large share of the total RD expenditure of biopharmaceutical companies, is anticipated to propel market growth in near future. There has been a significant rise in biologics and temperature-sensitive drugs in clinical trials.

Most clinical trials are currently being conducted in developing economies. The increasing cost of clinical trials and complications in the recruitment of patients have encouraged biopharmaceutical companies to outsource clinical trials to regions such as Asia Pacific, Latin America, Central Eastern Europe, and the Middle East. Disease variation in developing economies further aids biopharmaceutical companies in performing clinical trials on rare diseases. Some regions, such as Asia Pacific, also provide greater economic benefits to biopharmaceutical companies, as governments in Singapore and China allocate funds to promote biomedical research. In Latin America, patient recruitment is easy due to reduced language barriers, which can help obtain informed consent easily, resulting in a faster clinical trial process.

Gather more insights about the market drivers, restrains and growth of the Clinical Trial Supplies Market

Detailed Segmentation:

Clinical Phase Insights

Phase III led the market and accounted for 52.75% of the global revenue in 2023. Phase III clinical trials are more complex when compared to other phases. The list of FDA-approved phase III drugs is comparatively smaller, and the complexity associated with this phase is the highest. The failure rate in this phase is also the highest as the sample size and study design require complex dosing at an optimum level. Loss associated with failure is with respect to human and financial issues, and most failures are due to non-compliance with safety efficacy standards. Such a scenario is expected to surge the demand for efficient clinical trials supply and logistics, which, in turn, is expected to impact market growth positively.

Product Service Insights

Supply chain management accounted for the largest market revenue share in 2023.This scenario exists in most regions worldwide, except in the U.S., wherein the manufacturing segment is also expected to grow at a lucrative rate. The recent COVID-19 pandemic led to a wide disruption in the supply chain along with its impact on the lives of the citizens. This propelled the U.S. to become even more self-reliant, eventually focusing more on manufacturing services. 

Therapeutic Use Insights

Oncology led the market in 2023 and is attributable to presence of a huge RD pipeline. Majority of oncology drugs require temperature-sensitive distribution, which is expected to fuel the demand for cold chain distribution. Oncology clinical trials are designed to diagnose, manage, and treat cancer associated symptoms. Clinical trial supplies in oncology include primary and secondary packaging.

End-use Insights

Pharmaceuticals accounted for the largest market share of 42.48% in 2023. Pharmaceutical companies spend substantial investments in RD to create novel medications and treatments. To acquire information about the efficacy and safety of their products, clinical trials are an essential step in a drug development process. Therefore, based on end-use, clinical trial supplies industry is segmented into pharmaceuticals, biologics, medical devices, and others.

Regional Insights

North America accounted for the largest market share of 55.49% in 2023. The region conducts the maximum number of clinical trials amongst all, which is a major driver for clinical trial supplies industry growth. Moreover, presence of key players, coupled with advanced technology penetration are major factors responsible for the dominance of this region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The S. donor egg IVF services market size was estimated at USD 398.5 million in 2024 and is projected to grow at a CAGR of 4.4% from 2025 to 2030
  
  
• The global electro-medical and electrotherapeutic apparatus market size was estimated at USD 66.2 billion in 2024 and is projected to grow at a CAGR of 6.4% from 2025 to 2030.

Key Clinical Trial Supplies Companies:

• Almac Group
• Biocair
• Catalent Inc.
• KLIFO
• Movianto
• PCI Pharma Services
• Sharp Services, LLC
• Thermo Fischer Scientific Inc.
• Marken
• PAREXEL International Corporation

Clinical Trial Supplies Market Segmentation

Grand View Research has segmented the global clinical trial supplies market based on clinical phase, product/service, end-use, therapeutic use, and region:

Clinical Trial Supplies Clinical Phase Outlook (Revenue, USD Billion, 2018 - 2030)

• Phase I
• Phase II
• Phase III
• Others

Clinical Trial Supplies Product/Service Outlook (Revenue, USD Billion, 2018 - 2030)

• Manufacturing
• Storage distribution
  • Cold chain based
  • Non-cold chain based
• Supply chain management

Clinical Trial Supplies End-Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Pharmaceuticals
• Biologics
• Medical device
• Others

Clinical Trial Supplies Therapeutic Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Oncology
• CNS
• Cardiovascular
• Infectious disease
• Metabolic disorders
• Others

Clinical Trial Supplies Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America
  • US              
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Recent Developments

• In February 2023,Catalent completed a USD 2.2 million expansion of its clinical supply facility in Singapore. This expansion has enlarged the site's footprint to 31,000 square feet, providing room for installing 35 new freezers dedicated to ultra-low temperature (ULT) storage.
• In January 2023,ASLAN Pharmaceuticals and Thermo Fisher Scientific entered into a partnership to manufacture a high concentration formulation of Eblasakimab for upcoming studies. Thermo Fisher Scientific will contribute its expertise in biologic manufacturing and scale-up capacity to oversee a clinical supply of Eblasakimab for the anticipated Phase 3 studies.
• In July 2023,Almac Sciences announced the opening of a custom-built GMP warehouse and dispatch hub at Almac Group’s global headquarters in Craigavon, UK. The facility will support all the manufacturing and lab activities of Active Pharmaceutical Ingredients from development to their commercialization.

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.